Extractable’s & Leachable’s
The objective of Extractable’s & Leachable’s Testing for Pharmaceutical products is to determine and evaluate any toxicological concerns that may result from such interactions - assessing the purity of a final product is a key task when releasing pharmaceutical products on the market. Historically, it was limited to impurities that were created during the production process and the degradation of the pharmaceutical product.
Currently, it is essential to assess the diffusion of mobile compounds from the materials used for the manufacturing process and storage of pharmaceutical product. The USFDA & the EMA are bringing awareness to how different production systems, drug delivery systems, and container-closure systems interact with the finished pharmaceutical product.
The FDA states that: “Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality or purity of the drug beyond the official or established requirements.” (From the US FDA, Code of Federal Regulations, 21CFR211.94)
The FDA defines Extractable’s as “Organic and inorganic chemical species that can be released from the surfaces of components used in the manufacture and storage of drug products under laboratory conditions (accelerated or exaggerated temperatures, solvents or surface exposure).”
The FDA defined Leachable’s as “Organic and inorganic chemical species that can be released from the surfaces of components used in the manufacture and storage of drug products under conditions of normal use.”
Leachable species may be found in a variety of sources such as:
- Manufacturing (Filters, Single-use bags, Tubing…)
- Primary packaging — External components (Container-closure system (vials, caps, lids and foils), Single-use systems (syringes and intravenous bags))
- Primary packaging — Internal components (Gaskets and O-rings, Valves, Springs)
- Secondary and tertiary packaging (Labels and adhesives, Inks and colourings)
Leachables from the production and packaging processes that enter pharmaceutical items must be tracked and detected. Patient safety is ensured by the compiled data, which enables a toxicological evaluation of any leachables discovered.
Our laboratory begins by learning everything there is to know about your packaging & manufacturing system in order to provide a thorough picture of all potential sources of leachables. Our team can anticipate and identify possible sources of risk linked with leachable impurities through strategic screening tests thanks to our experience in method development for a controlled extractables research and our extensive understanding of leachable substances and regulations.
Medistri’s Laboratory provides GMP-compliant leachables method validation for use in GMP stability testing and storage programs and are able to support a variety of closure or drug delivery systems — including:
- Pre-filled Syringes.
- Pharmaceutical Vials.
- Large Volume Parenteral Products.
- Orally inhaled and nasal drug products (OINDP).
- Single-use and disposable medical equipment.
- Printed packaging.
- Secondary packaging migration behaviour.
- Medical Devices (ISO 10993–19).
- Drug Deliver Systems.
Medistri's contract Laboratory is located in the heart of Switzerland to continuously serve the countries most innovative universities, research institutes, start-up companies & large enterprises from the Pharmaceutical, MedTech & BioTech industries.
Created for start-up companies and early-stage products, Medistri's manufacturing team can offer primary, secondary, and tertiary packaging solutions that fit your strategic & regulatory requirements.
From manufacturing to product assembly and certification, leverage our team's expertise to find the custom solutions that fits your timeline requirements.
Our Quality Certificates
Explore our list quality certificates and discover why the world's most innovative healthcare companies choose to work with Medistri.
Are you ready to get started?
Contact us and our qualified team will respond.